No connection

Search Results

ARCT vs SMTI

ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%
SMTI
Sanara MedTech Inc.
BEARISH
Price
$20.77
Market Cap
$190.4M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARCT
--
SMTI
--
Forward P/E
ARCT
-1.61
SMTI
40.73
P/B Ratio
ARCT
0.89
SMTI
31.28
P/S Ratio
ARCT
2.31
SMTI
1.85
EV/EBITDA
ARCT
0.22
SMTI
18.8

Profitability

Gross Margin
ARCT
-36.79%
SMTI
92.71%
Operating Margin
ARCT
-435.06%
SMTI
10.5%
Profit Margin
ARCT
-80.19%
SMTI
-36.43%
ROE
ARCT
-28.92%
SMTI
-1.75%
ROA
ARCT
-15.5%
SMTI
7.1%

Growth

Revenue Growth
ARCT
-68.4%
SMTI
4.7%
Earnings Growth
ARCT
--
SMTI
--

Financial Health

Debt/Equity
ARCT
0.12
SMTI
8.13
Current Ratio
ARCT
6.64
SMTI
1.8
Quick Ratio
ARCT
6.5
SMTI
1.53

Dividends

Dividend Yield
ARCT
--
SMTI
--
Payout Ratio
ARCT
0.0%
SMTI
0.0%

AI Verdict

ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
SMTI BEARISH

SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.

Strengths
Exceptional Gross Margin (92.71%) indicating strong product pricing power
Positive Operating Margin (10.50%) suggesting core business viability
Adequate short-term liquidity with a Current Ratio of 1.80
Risks
Extreme leverage with a Debt/Equity ratio of 8.13
Critical financial health indicated by Piotroski F-Score of 2/9
Chronic inability to meet earnings estimates with severe negative surprises

Compare Another Pair

ARCT vs SMTI: Head-to-Head Comparison

This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Sanara MedTech Inc. (SMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile